Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplenex vs Separate Drops in Glaucoma
NCT06761313Phase 4Active, not recruiting
- Sponsor
- Federal University of São Paulo
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bimatoprost + brimonidine + timolol in Glaucoma (2 arms), sponsored by Federal University of São Paulo. Primary endpoints: Intraocular Pressure at 12 weeks, Ocular Surface Disease Index at 12 weeks and 7 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
bimatoprost + brimonidine + timolol
03
Conditions
Glaucoma
Beyond the preview
Go deeper on NCT06761313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06761313.